respiratory syncytial virus
FDA starts review of Sanofi, AZ antibody for RSV prevention
Phil Taylor
AstraZeneca, infectious disease, nirsevimab, respiratory syncytial virus, Sanofi
0 Comment
RSV vaccine race in balance as FDA sets May date for Pfizer decision
Phil Taylor
fda, GSK, Pfizer, regulatory, respiratory syncytial virus, vaccine
0 Comment
AZ, Sanofi get first green light for RSV prophylactic antibody
Phil Taylor
antibody, AstraZeneca, Beyfortus, nirsevimab, paediatrics, prevention, respiratory syncytial virus, Sanofi
0 Comment
News/ News/ Sales and Marketing
After Haleon spinoff, GSK raises forecasts on ‘strong’ Q3
Phil Taylor
Financial, GlaxoSmithKline, respiratory syncytial virus, Sales and Marketing, Shingrix, vaccines
0 Comment
Pfizer says maternal RSV shot gives strong protection to newborns
Phil Taylor
GlaxoSmithKline, maternal, paediatric, Pfizer, respiratory syncytial virus, vaccine
0 Comment
EU regulator lifts GSK amid torrid week for company’s pipeline
Phil Taylor
cabotegravir, ema, GlaxoSmithKline, respiratory syncytial virus, vaccine
0 Comment
GSK says RSV vaccine shows 94% efficacy in severe disease
Phil Taylor
Bavarian Nordic, GlaxoSmithKline, infectious disease, Johnson & Johnson, Moderna, Pfizer, respiratory syncytial virus, vaccine
0 Comment
CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevention
Phil Taylor
antibody, AstraZeneca, Beyfortus, CHMP, GlaxoSmithKline, nirsevimab, Pfizer, respiratory syncytial virus, Sanofi
0 Comment